| Literature DB >> 28493924 |
Leigh E Charvet1, Jie Yang2, Michael T Shaw1, Kathleen Sherman1, Lamia Haider3, Jianjin Xu4, Lauren B Krupp1.
Abstract
Cognitive impairment affects more than half of all individuals living with multiple sclerosis (MS). We hypothesized that training at home with an adaptive online cognitive training program would have greater cognitive benefit than ordinary computer games in cognitively-impaired adults with MS. This was a double-blind, randomized, active-placebo-controlled trial. Participants with MS were recruited through Stony Brook Medicine and randomly assigned to either the adaptive cognitive remediation (ACR) program or active control of ordinary computer games for 60 hours over 12 weeks. Training was remotely-supervised and delivered through a study-provided laptop computer. A computer generated, blocked stratification table prepared by statistician provided the randomization schedule and condition was assigned by a study technician. The primary outcome, administered by study psychometrician, was measured by change in a neuropsychological composite measure from baseline to study end. An intent-to-treat analysis was employed and missing primary outcome values were imputed via Markov Chain Monte Carlo method. Participants in the ACR (n = 74) vs. active control (n = 61) training program had significantly greater improvement in the primary outcome of cognitive functioning (mean change in composite z score±SD: 0·25±0·45 vs. 0·09±0·37, p = 0·03, estimated difference = 0·16 with 95% CI: 0·02-0·30), despite greater training time in the active control condition (mean±SD:56·9 ± 34·6 vs. 37·7 ±23 ·8 hours played, p = 0·006). This study provides Class I evidence that adaptive, computer-based cognitive remediation accessed from home can improve cognitive functioning in MS. This telerehabilitation approach allowed for rapid recruitment and high compliance, and can be readily applied to other neurological conditions associated with cognitive dysfunction. TRIAL REGISTRATION: Clinicaltrials.gov NCT02141386.Entities:
Mesh:
Year: 2017 PMID: 28493924 PMCID: PMC5426671 DOI: 10.1371/journal.pone.0177177
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Primary outcome: Neuropsychological composite.
| Neuropsychological Test | Cognitive Domain | Study Outcome |
|---|---|---|
| Paced Auditory Serial Addition Test (PASAT) | Processing Speed | 2 Second Trial |
| WAIS-IV Letter Number Sequence | Working Memory | Total Score |
| WAIS-IV Digit Span Backwards | Working Memory | Total Score |
| Selective Reminding Test (SRT) | Verbal Learning | Total Recall across Learning Trials |
| Brief Visuospatial Memory Test-Revised (BVMT-R) | Visual Learning | Total Recall across Learning Trials |
| Delis-Kaplan Executive Function System Trails | Visual Scanning | Composite (Average of Number and Letter Sequencing Trials) |
1 Paced Auditory Serial Addition Test[23],
2,3 WAIS-IV Letter Number Sequencing and Digit Span[24],
4 Selective Reminding Test[25],
5 Brief Visuospatial Memory Test-Revised[26],
6 Delis-Kaplan Executive Function System Trails[27, 28].
Fig 1Consort flow diagram.
Demographic and clinical characteristics.
| Demographic Characteristics | ACR Condition (n = 74) | Active Control Condition (n = 61) | Full Sample (n = 135) |
|---|---|---|---|
| Sex (n,% Female) | 50, 67·57% | 54,88·52% | 104,77·04% |
| Age (mean years±SD) | 48±13 | 52±11· | 50±12 |
| Education (mean Years±SD) | 14·82±2·37 | 15·05±2·55 | 14·93±2·45 |
| Race (n, %): | - | - | - |
| White | 63,85·14% | 51,83·61% | 114,84·44% |
| Black/African American | 6,8·11% | 4,6·56% | 10,7·41% |
| Other/Unknown | 5,6·76% | 6,9·84% | 11,8·15% |
| Ethnicity—Hispanic or Latino (n, %): | 7, 9·86% | 3,5·26% | 10,7·81% |
| Clinical Characteristics | - | - | - |
| MS Subtype (n, %) | |||
| Relapsing-Remitting | 51 (69%) | 39 (64%) | 89 (66%) |
| Primary Progressive | 3(<1%) | 4 (<1%) | 7 (<1%) |
| Secondary Progressive | 20 (27%) | 15 (23%) | 35 (26%) |
| Disease Duration (mean years±SD) | 11·9±10·9 | 13·5±10·0 | 12·62±10·46 |
| EDSS (median score±IQR) | 3·50±4·00 | 3·50±4·00 | 3·50±4·00 |
| 25 Foot Timed Walk (median seconds, min-max) | 5·7 (3·5–28·75) | 6·3 (3·25–24·75) | 5·9 (3·25–28·75) |
| Screening SDMT z score (mean score±SD) | -2·10±0·99 | -2·10±1·01 | -2·10±0·99 |
Composite score differences between conditions.
| Treatment Condition | Mean ± SD baseline z-score | Mean ± SD end z-score | Mean ± SD change z-score |
|---|---|---|---|
| ACR | -0.77 ± 0.73 | -0.68 ± 0.76 | 0·25 ± 0·45 |
| Active Control | -0.86 ± 0.77 | -0.60 ± 0.85 | 0·09 ± 0·37 |
* 5 subjects who dropped out the study did not have end z-scores and hence were not included in calculating end z-score and change in z-score.
Fig 2Change in z score across measures by condition.
*Indicates a significant difference corresponding to a p value<0.05. Higher scores indicate improvement.
Fig 3Total time spent in program by condition.
*Greater time was spent in program by the active control condition (p = 0.006).